Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008797:Metyrapone; D008875:Middle Aged; D009824:Ointments / Q000009:adverse effects; D010912:Pituitary-Adrenal Function Tests; D012871:Skin Diseases / Q000188:drug therapy*; D013256:Steroids / Q000097:blood*; D014631:Valerates / Q000627:therapeutic use
D015065:17-Hydroxycorticosteroids; D009824:Ointments; D013256:Steroids; D014631:Valerates; D001623:Betamethasone; D008797:Metyrapone